Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYRoche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degenerationPREV STORYFirst US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product